Treatment, outcomes poorer in AML with chromosome abnormality
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
Blood cancer
Olverembatinib named ALL breakthrough therapy in China
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
Tuspetinib study in newly diagnosed AML moves to higher dose
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being explored in a clinical trial…
Tuspetinib as part of triple-combo therapy showing potential in AML
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
Cancer vaccine galinpepimut-S may improve AML survival: Analysis
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
Blincyto approved in Europe for newly diagnosed adults with B-ALL
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
FDA approves Grafapex combo for bone marrow transplant with AML
The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
Calquence combo approved by FDA for untreated mantle cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
FDA gives LYT-200 fast track status as potential AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
Antipsychotic clozapine raises blood cancer rates; overall risk is small
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
